Nventric Corporation – Trademark Portfolio

Entity Type: 03

Nventric Corporation holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 9 filings in this category. Currently, 8 trademarks are registered. Notable registered marks include CAPTEVO, ULTRIVA, AGILARON, EVOGLIDE, and EXPANDRA.

A-1501, 149 Yangpyeong-ro,

Yeongdeungpo-gu Seoul 07207

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

AGILARON
AGILARON
Registered 2025
EXPANDRA
EXPANDRA
Registered 2025
CORETRAX
CORETRAX
Abandoned 2024
CAPTEVO
CAPTEVO
Registered 2024
EVOGLIDE
EVOGLIDE
Registered 2024
ULTRIVA
ULTRIVA
Registered 2024
FLEX RHV
FLEX RHV
Registered 2023
FLEX DHV
FLEX DHV
Registered 2023

Trademark Classifications

Nventric Corporation's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (9 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Nventric Corporation have?

Nventric Corporation has 9 U.S. trademarks filed with the USPTO. Of these, 8 registered, 1 abandoned.

What trademark classes does Nventric Corporation file in?

Nventric Corporation files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Nventric Corporation's most well-known trademarks?

Nventric Corporation's registered trademark portfolio includes well-known marks such as CAPTEVO, ULTRIVA, AGILARON, EVOGLIDE, and EXPANDRA. These are among 8 currently registered trademarks in the portfolio.

What is Nventric Corporation's trademark registration success rate?

Nventric Corporation has a 89% trademark registration rate, with 8 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.